SCHEDULE 13G/A: Vanguard Group Adjusts Passive Stake in Caribou Biosciences, Now Below 5% Threshold

The Vanguard Group has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 4.86% in Caribou Biosciences Inc., indicating a passive investment below the 5% reporting threshold.

Summary

• The Vanguard Group, a major investment adviser, has filed an Amendment No. 2 to its Schedule 13G regarding its holdings in Caribou Biosciences Inc.
• As of March 31, 2025, Vanguard beneficially owns 4,522,032 shares of Caribou Biosciences' Common Stock.
• This ownership represents 4.86% of the class of securities, placing Vanguard below the 5% threshold for certain reporting requirements.
• Vanguard holds sole voting power over 0 shares, shared voting power over 35,754 shares, sole dispositive power over 4,457,177 shares, and shared dispositive power over 64,855 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Caribou Biosciences Inc.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative. While Vanguard maintains a significant holding, the reduction of its stake below the 5% threshold (implied by this being an amendment) can be interpreted as a decrease in conviction or a portfolio rebalancing, which is generally viewed unfavorably by the market.

Positives

• The Vanguard Group, a significant institutional investor, continues to hold a substantial number of shares (4,522,032) in Caribou Biosciences Inc., indicating continued investment interest.
• The filing confirms that Vanguard's investment is passive and held in the ordinary course of business, suggesting no immediate intent to influence company control.

Negatives

• The reported beneficial ownership of 4.86% is below the 5% threshold, which, given this is an amendment, implies a reduction in Vanguard's stake from a previous filing where they likely held 5% or more.
• A reduction in stake by a major institutional investor like Vanguard could be perceived as a negative signal by the market.

Risks

• The document does not explicitly state risks for Caribou Biosciences Inc.; it is a disclosure of an investor's ownership position.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Caribou Biosciences Inc.'s future performance or operations.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Statement from The Vanguard Group's Head of Global Fund Administration, Ashley Grim)

Industry Context

This filing is a routine disclosure of institutional ownership, common in the financial industry. It reflects The Vanguard Group's ongoing investment activities as a large asset manager, rather than specific trends within the biotechnology or pharmaceutical industry where Caribou Biosciences operates. The reduction in stake below 5% is a common event for passive investors who adjust their portfolio weightings.

Stakeholder Impact

• Shareholders: The disclosure of Vanguard's reduced stake may influence investor sentiment and potentially the stock price, as large institutional movements are often closely watched.
• Company Management: Awareness of changes in significant institutional ownership can inform investor relations strategies.

Key Dates

Keywords

Caribou Biosciences, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Passive Investment